UNITY Biotechnology (UBX) Competitors $0.18 -0.12 (-40.43%) Closing price 07/8/2025Extended Trading$0.18 0.00 (0.00%) As of 07/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UBX vs. BIVI, ALVR, BTAI, AIMD, ABP, BCLI, PHIO, KZIA, CSCI, and CVMShould you be buying UNITY Biotechnology stock or one of its competitors? The main competitors of UNITY Biotechnology include BioVie (BIVI), AlloVir (ALVR), BioXcel Therapeutics (BTAI), Ainos (AIMD), Abpro (ABP), Brainstorm Cell Therapeutics (BCLI), Phio Pharmaceuticals (PHIO), Novogen (KZIA), COSCIENS Biopharma (CSCI), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry. UNITY Biotechnology vs. Its Competitors BioVie AlloVir BioXcel Therapeutics Ainos Abpro Brainstorm Cell Therapeutics Phio Pharmaceuticals Novogen COSCIENS Biopharma CEL-SCI BioVie (NASDAQ:BIVI) and UNITY Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Which has more volatility and risk, BIVI or UBX? BioVie has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, UNITY Biotechnology has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Which has stronger earnings & valuation, BIVI or UBX? UNITY Biotechnology is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$32.12M-$79.10-0.09UNITY BiotechnologyN/AN/A-$25.99M-$1.62-0.11 Does the media prefer BIVI or UBX? In the previous week, BioVie had 1 more articles in the media than UNITY Biotechnology. MarketBeat recorded 2 mentions for BioVie and 1 mentions for UNITY Biotechnology. UNITY Biotechnology's average media sentiment score of 1.89 beat BioVie's score of 1.56 indicating that UNITY Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment BioVie Very Positive UNITY Biotechnology Very Positive Do analysts recommend BIVI or UBX? UNITY Biotechnology has a consensus target price of $3.75, suggesting a potential upside of 1,994.97%. Given UNITY Biotechnology's higher possible upside, analysts plainly believe UNITY Biotechnology is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00UNITY Biotechnology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders hold more shares of BIVI or UBX? 4.6% of BioVie shares are held by institutional investors. Comparatively, 29.5% of UNITY Biotechnology shares are held by institutional investors. 2.4% of BioVie shares are held by company insiders. Comparatively, 5.8% of UNITY Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is BIVI or UBX more profitable? BioVie's return on equity of -100.88% beat UNITY Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -100.88% -78.49% UNITY Biotechnology N/A -246.82%-58.81% SummaryUNITY Biotechnology beats BioVie on 9 of the 14 factors compared between the two stocks. Get UNITY Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UBX vs. The Competition Export to ExcelMetricUNITY BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.08M$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.1120.3628.1819.72Price / SalesN/A290.30439.19110.06Price / CashN/A42.3835.5357.53Price / Book0.467.768.235.67Net Income-$25.99M-$55.11M$3.23B$257.51M7 Day PerformanceN/A0.19%-0.61%-0.16%1 Month Performance-76.93%10.80%6.63%9.89%1 Year Performance-88.15%-0.68%27.07%15.08% UNITY Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UBXUNITY Biotechnology4.658 of 5 stars$0.18-40.4%$3.75+1,995.0%-88.4%$3.08MN/A-0.1160Positive NewsUpcoming EarningsGap DownHigh Trading VolumeBIVIBioVie1.0653 of 5 stars$6.62-7.3%N/A+62.6%$12.31MN/A-0.0810Positive NewsGap UpALVRAlloVirN/A$2.43-2.8%N/A-87.3%$12.25MN/A-0.12110High Trading VolumeBTAIBioXcel Therapeutics4.2269 of 5 stars$2.02+2.5%$42.60+2,008.9%-90.9%$12.24M$2.27M-0.1590Positive NewsAIMDAinos1.5289 of 5 stars$2.88-3.4%N/A-25.5%$12.07M$20K-0.4540News CoverageABPAbproN/A$0.20-4.2%$4.00+1,921.2%N/A$12.03M$183K0.0015Positive NewsBCLIBrainstorm Cell Therapeutics1.296 of 5 stars$1.20flatN/A-80.2%$11.81MN/A-0.3640News CoveragePHIOPhio Pharmaceuticals2.5729 of 5 stars$2.41+4.3%$14.00+480.9%-48.4%$11.57MN/A-0.3810News CoverageKZIANovogen3.7133 of 5 stars$11.43+5.8%$14.00+22.5%-64.4%$11.54M$1.51M0.0012Analyst RevisionCSCICOSCIENS BiopharmaN/A$3.62+2.5%N/AN/A$11.39M$9.03M-0.6220Positive NewsCVMCEL-SCI0.1707 of 5 stars$3.63+2.8%N/A-91.4%$11.01MN/A-7.5643Gap DownHigh Trading Volume Related Companies and Tools Related Companies BioVie Competitors AlloVir Competitors BioXcel Therapeutics Competitors Ainos Competitors Abpro Competitors Brainstorm Cell Therapeutics Competitors Phio Pharmaceuticals Competitors Novogen Competitors COSCIENS Biopharma Competitors CEL-SCI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UBX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UNITY Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share UNITY Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UBX Stock Alerts